• 1
    Negro JM, Wheeler AW, Hernandez J, et al. Comparison of the efficacy and safety of two preseasonal regimens of glutaraldehyde modified, tyrosine-adsorbed Parietaria pollen extract over a period of three years in monosensitive patients. Allergol Immunopathol (Madr) 1999;27:153164.
  • 2
    Lee LK, Kniker WT, Campos T. Aggressive coseasonal immunotherapy in mountain cedar pollen allergy. Arch Otolaryngol 1982;108:787794.
  • 3
    Bousquet J, Lockey FR, Malling H-J. Allergy immunotherapy: therapeutic vaccines for allergic diseases. WHO position paper. Allergy 1998;53:142.
  • 4
    Fahy JV. Reducing IgE levels as a strategy for the treatment of asthma. Clin Exp Allergy 2000;30 Suppl 1:1621.
  • 5
    Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341:468475.
  • 6
    Valovirta E. PAT – The Preventative Allergy Treatment Study – design and preliminary results. Wien Med Wochenschr 1999;149:442443.
  • 7
    Schädlich PK & Brecht JG. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoeconomics 2000;17:3752.
  • 8
    Akdis CA & Blaser K. Mechanisms of allergen-specific immunotherapy. Allergy 2000;55:522530.DOI: 10.1034/j.1398-9995.2000.00120.x
  • 9
    Durham SR & Till SJ. Immunologic changes associated with allergen immunotherapy. J Allergy Clin Immunol 1998;102:157164.
  • 10
    Ulrich JT & Myers KR. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. In: PowellMF, NewmanMJ, editors. Vaccine design: the subunit and adjuvant approach. New York: Plenum Press, 1995:495524.
  • 11
    Baldridge JR, Yorgensen Y, Ward JR, Ulrich JT. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine 2000;18:24162425.DOI: 10.1016/s0264-410x(99)00572-1
  • 12
    Newman KD, Sowsnowski DL, Kwon GS, Samuel J. Delivery of MUC1 mucin peptide by poly(d,l-lactic-co-glycolic acid) microspheres induces type 1 helper immune responses. J Pharm Sci 1998;87:14211427.
  • 13
    Koutsoukos M, Leroux G, Vandepaplier EP, Slaoui M, Pala P. Induction of cell mediated immune responses in man with vaccines against Herpes simplex virus based on glycoprotein D. 34th ICAAC meeting 1994, M8, 217.
  • 14
    Mikloska Z, Rückholdt M, Ghadiminejad I, Dunckly H, Denis M, Cunningham AL. Monophosphoryl lipid A and QS21 increase CD8 T lymphocyte cytotoxicity to herpes simplex virus-2 infected cell proteins 4 and 27 through IFN-gamma and IL-12 production. J Immunol 2000;164:51675176.
  • 15
    Thoelen S. An overview on a novel adjuvanted prophylactic hepatitis B vaccine. Acta Gastroenterol Belg 2000;63:185186.
  • 16
    Thoelen S, Van Damme P, Mathei C, et al. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 1998;16:708714.DOI: 10.1016/s0264-410x(97)00254-5
  • 17
    Heppner DG, Gordon DM, Gross M, et al. Safety immunogenicity and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes. J Infect Dis 1996;174:361366.
  • 18
    Mitchell MS. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol 1998;25:623635.
  • 19
    Overell BG, Spackman DA, Wheeler AW, Pfeiffer P. Standardisation of glutaraldehyde-modified, tyrosine-adsorbed allergen extracts [in German]. Allergologie 1991;14:110115.
  • 20
    Wheeler AW, Jenkins PM, Moran DM. Chemical modification of crude timothy grass pollen extract. II. Class and specificity of antibodies induced by chemically modified timothy grass pollen extract. Int Arch Allergy Appl Immunol 1976;50:709728.
  • 21
    Moran DM, Wheeler AW, Overell BG, Woroniecki SR. Chemical modification of crude timothy grass pollen extract. III. The effect of glutaraldehyde-induced aggregation on antigenic and immunogenic properties. Int Arch Allergy Appl Immunol 1977;55:315321.
  • 22
    Kahler H, Stuwe H, Cromwell O, Fiebig H. Reactivity of T cells with grass pollen extract and allergoid. Int Arch Allergy Immunol 1999;120:146157.
  • 23
    Wheeler AW, Moran DM, Robins BE, Driscoll A. l-Tyrosine as an immuno-logical adjuvant. Int Arch Allergy Appl Immunol 1982;69:113119.
  • 24
    Wheeler AW & Lees B. Standardisation of tyrosine-adsorbed glutaralde-hyde-modified grass pollen extract (Pollinex® Grass) [in Slovak]. Klin Immunol Alergol 2000;10:3842.
  • 25
    EU notes for guidance on allergen products, 1996 (CPMP/BWP/243/96).
  • 26
    Ph Eur, Allergen products (Producta Allergenica), 1997:10631068.
  • 27
    El Shami AS & Alalba O. Liquid-phase in vitro allergen-specific IgE assay with in situ immobilization. In: Said El ShamiA, MerrettTG, editors. Allergy and molecular biology. Advances in the Biosciences. Vol. 74. Oxford: Pergamon Press, 1989:191201.
  • 28
    Durham SR, Ying S, Varney VA, et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996;97:13561365.
  • 29
    Wheeler AW, Ulrich T, Marshall J. Potential enhancement of the immunotherapeutic effect of allergy vaccines by a Th1-inducing adjuvant, MPL. Allergy 1998;53 Suppl 51:213.
  • 30
    Ulrich JT & Wheeler AW. Allergen formulation. 1998 World patent (PCT) WO 98/44947.
  • 31
    Salkowski CA, Gregory RD, Vogel SN. Lipopolysaccharide and monophosphoryl lipid A differentially regulated interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages. Infect Immun 1997;65:32393247.
  • 32
    Johansson SG, Miller AC, Mullan N, Overell BG, Tees EC, Wheeler A. Glutaraldehyde-pollen-tyrosine: clinical and immunological studies. Clin Allergy 1974;4:255263.
  • 33
    Wheeler AW. Overview of immunologic adjuvants for use in specific immunotherapy: past, present and future [in German]. Allergo J 1997;6:421426.
  • 34
    Hopkins M, Woroniecki SR, Lees B, Richardson D, Wheeler AW. The potential immunotherapeutic enhancing effect of the Th1-enhancing adjuvant MPL on allergy vaccines and the development of quality control procedures [Abstract]. Allergy 1999;54 Suppl 52:101.
  • 35
    Hickman BE, Wheeler AW, Fox B, Nüsslein HG, Renner B. Studies on the immunogenicity of tyrosine-adsorbed, glutaraldehyde-modified extracts of birch, alder and hazel tree pollens (TA Baumpollen) [in German]. Allergologie 1990;13:1620.
  • 36
    Malling H-J, Skov PS, Permin H, Norn S, Weeke B. Basophil histamine release and humoral changes during immunotherapy. Dissociation between basophil-bound specific IgE, serum value, and cell sensitivity. Allergy 1982;37:187190.